NYSE:MRKPharmaceuticals
Will Merck’s (MRK) Early Royalty-Free HIV PrEP Licensing Strategy Redefine Its Global Health Narrative
In July 2026, Merck announced an early, multi-pronged access plan for its investigational once-monthly HIV PrEP pill alimatravir (MK-8527), including royalty-free voluntary licensing with seven generic manufacturers to supply 129 low- and middle-income countries following potential regulatory approvals.
This move, which includes regional manufacturing in Africa and Latin America and licensing deals signed even before Phase 3 enrollment completion, marks a first-of-its-kind early access...